L55 - LPL Bengaluru Reference Lab

#17/1, "The Address" Opp Cessna Business

Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P
Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

SwasthFit Pro 3 (with health review consultation)

AMYLASE, SERUM 91.00 U/L 37.00 - 125.00

(IFCC)

Comments
Amylase is produced in the Pancreas and most of the elevation in serum is due to increased rate of Amylase entry into the
blood stream / decreased rate of clearance or both. Serum Amylase rises within 6 to 48 hours of onset of Acute
pancreatitis in 80% of patients, but is not proportional to the severity of the disease. Activity usually returns to normal in 3-
5 days in patients with milder edematous form of the disease. Values persisting longer than this period suggest continuing
necrosis of pancreas or Pseudocyst formation. Approximately 20% of patients with Pancreatitis have normal or near normal
activity. Hyperlipemic patients with Pancreatitis also show spuriously normal Amylase levels due to suppression of
Amylase activity by triglyceride. Low Amylase levels are seen in Chronic Pancreatitis, Congestive Heart failure, 2nd & 3rd
trimesters of pregnancy, Gastrointestinal cancer & bone fractures.

GLUCOSE, FASTING (F), PLASMA 98.00 mg/dL 70.00 - 100.00

(Hexokinase)

CARDIO C-REACTIVE PROTEIN (hsCRP), SERUM 2.80

(Immunoturbidimetry)

Interpretation

| CARDIO CRP IN mg/L | CARDIOVASCULAR RISK |

|-----------------------|--------------------------------------|
| <1 | Low |
|-----------------------|--------------------------------------|
| 1-3 | Average |
|-----------------------|--------------------------------------|
| 3-10 | High |
|-----------------------|--------------------------------------|
| >10 | Persistent elevation may represent |
| | Non cardiovascular inflammation |

Note: To assess vascular risk, it is recommended to test hsCRP levels 2 or more weeks apart and calculate
the average

Comments
High sensitivity C Reactive Protein (hsCRP) significantly improves cardiovascular risk assessment as it is a strongest
predictor of future coronary events. It reveals the risk of future Myocardial infarction and Stroke among healthy men and
women, independent of traditional risk factors. It identifies patients at risk of first Myocardial infarction even with low to
moderate lipid levels. The risk of recurrent cardiovascular events also

* Not in NABL scope Page 1 of 11

L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P
Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

correlates well with hsCRP levels. It is a powerful independent risk determinant in the prediction of incident Diabetes.

LIPID SCREEN, SERUM

(Enzymatic)

Cholesterol, Total 200.00 mg/dL <200.00

Triglycerides 201.00 mg/dL <150.00

HDL Cholesterol 61.00 mg/dL >50.00

LDL Cholesterol, Calculated 98.80 mg/dL <100.00

VLDL Cholesterol,Calculated 40.20 mg/dL <30.00

Interpretation

| REMARKS | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL|

| | CHOLESTEROL| in mg/dL | in mg/dL |
| | in mg/dL | | |
|----------------|------------|--------------|----------------|
| Optimal | <200 | <150 | <100 |
|----------------|------------|--------------|----------------|
| Above Optimal | - | - | 100-129 |
|----------------|------------|--------------|----------------|
| Borderline High| 200-239 | 150-199 | 130-159 |
|----------------|------------|--------------|----------------|
| High | >=240 | 200-499 | 160-189 |
|----------------|------------|--------------|----------------|
| Very High | - | >=500 | >=190 |

Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week
apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
2. ATP III recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.
3. Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL.
Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL.

* Not in NABL scope Page 2 of 11

L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P
Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

C-REACTIVE PROTEIN; CRP, SERUM * 5.00 mg/L <3
(Immunoturbidimetry)

Comments
CRP is an acute phase reactant which is used in inflammatory disorders for monitoring course and effect of therapy. It is
most useful as an indicator of activity in Rheumatoid arthritis, Rheumatic fever, tissue injury or necrosis and infections.
As compared to ESR, CRP shows an earlier rise in inflammatory disorders which begins in 4-6 hrs, the intensity of the
rise being higher than ESR and the recovery being earlier than ESR. Unlike ESR, CRP levels are not influenced by
hematologic conditions like Anemia, Polycythemia etc.
FERRITIN, SERUM 16.00 ng/mL 10.00 - 291.00
(CLIA)

Note: Increase in serum ferritin due to inflammatory conditions (Acute phase response) can mask a diagnostically low
result

Comments
Serum ferritin appears to be in equilibrium with tissue ferritin and is a good indicator of storage iron in normal subjects and in
most disorders. In patients with some hepatocellular diseases, malignancies and inflammatory diseases, serum ferritin is a
disproportionately high estimate of storage iron because serum ferritin is an acute phase reactant. In such disorders iron
deficiency anemia may exist with a normal serum ferritin concentration. In the presence of inflammation, persons with
low serum ferritin are likely to respond to iron therapy.

Increased Levels
 Iron overload - Hemochromatosis, Thalassemia & Sideroblastic anemia
 Malignant conditions - Acute myeloblastic & Lymphoblastic leukemia, Hodgkin’s disease & Breast
carcinoma
 Inflammatory diseases - Pulmonary infections, Osteomyelitis, Chronic UTI, Rheumatoid arthritis, SLE,
burns
 Acute & Chronic hepatocellular disease

Decreased Levels
Iron deficiency anemia

HEPATITIS B SURFACE ANTIGEN;HBsAg, SERUM * Non Reactive Non Reactive

(Chemiluminescent Microparticle Immunoassay)

Note
1. All Reactive results are tested additionally by Specific antibody Neutralization assay . For further
confirmation Molecular assays are recommended
2. Discrepant results may be observed during pregnancy, patients receiving mouse monoclonal

* Not in NABL scope Page 3 of 11

L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P
Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

antibodies for diagnosis or therapy & mutant forms of HBsAg
3. For diagnostic purposes, results should be used in conjunction with clinical history and other hepatitis markers
for Acute or Chronic infection
4. For monitoring HBsAg levels, Quantitative HBsAg assay is recommended

Comment
Hepatitis B Virus ( HBV) is a member of the Hepadna virus family causing infections of the liver with extremely
variable clinical features. Hepatitis B is transmitted primarily by body fluids especially serum and also spread effectively
sexually and from mother to baby. In most individuals HBV hepatitis is self limiting, but 1-2% normal adolescents and
adults develop Chronic Hepatitis. Frequency of chronic HBV infection is
5-10% in immunocompromised patients and 80% in neonates. The initial serological marker of acute infection is
HBsAg which typically appears 2-3 months after infection and disappears 12-20 weeks after onset of symptoms.
Persistence of HBsAg for more than six months indicates development of carrier state or Chronic liver disease.
Uses
 Routine screening of blood and blood products to prevent transmission of Hepatitis B virus (HBV) to
recipients
 To diagnose suspected HBV infection and monitor the status of infected individuals
 To evaluate the efficacy of antiviral drugs
 For Prenatal Screening of pregnant women

LIPASE, SERUM 71.00 U/L 13.00 - 42.00

(Glycerol Kinase)

Comments
Pancreas is the major and primary source of serum lipase though lipases are also present in liver, stomach, intestine, WBC, fat
cells and milk. In acute pancreatitis, serum lipase becomes elevated at the same time as amylase and remains high for 7-10
days. Increased lipase activity rarely lasts longer than 14 days. Prolonged increase suggests poor prognosis or presence of a
cyst. The combined use of serum lipase and serum amylase is effective in ruling out acute pancreatitis.

Increased levels
 Acute & Chronic pancreatitis.
 Obstruction of pancreatic duct.
 Non pancreatic conditions like renal diseases, acute cholecystitis, intestinal obstruction, duodenal ulcer, alcoholism,
diabetic ketoacidosis and following endoscopic retrograde cholangiopancreatography.

* Not in NABL scope Page 4 of 11

L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

LIVER & KIDNEY PANEL, SERUM

(Spectrophotometry, Indirect ISE) Bilirubin Total
Bilirubin Direct Bilirubin Indirect AST (SGOT) ALT (SGPT) GGTP
Alkaline Phosphatase (ALP) Total Protein 0.20 mg/dL mg/dL mg/dL U/L U/L<1.00
U/L U/L g/dL
Albumin 0.10 g/dL 0.00 - 0.30
0.10 Potassium Chloride
A : G Ratio Urea Creatinine Uric Acid Calcium, Total Phosphorus Sodium <1.10
41 15.00 - 37.00
38 30 - 65
39 5 - 55
180 50 - 136
6.20 6.40 - 8.20
4.30 3.4 - 5.0
2.26 0.90 - 2.00
19.00 14.9 - 38.5
0.90 0.6 - 1.0
5.10 2.6 - 6.0
8.50 8.50 - 10.10
3.50 2.50 - 4.90
142.00 136.00 - 145.00
3.90 3.50 - mEq/L
mg/dL mg/dL mg/dL mg/dL mg/dL 5.10 mEq/L
106.00 mEq/L 98.00 - 107.00

THYROID PROFILE,TOTAL, SERUM

(CLIA)
T3, Total T4, Total TSH
2.00 ng/mL 0.60 - 1.81
9.00 ug/dL uIU/mL 5.01 - 12.45
8.60 0.35 - 5.50

Interpretation
|PREGNANCY |REFERENCE RANGE for TSH IN uIU/mL |
| |(As per American Thyroid |
| |Association) |
|--------------------------|----------------------------------|
|1st Trimester |0.10-2.50 |
|--------------------------|----------------------------------|
|2nd Trimester |0.20-3.00 |
|--------------------------|----------------------------------|
|3rd Trimester |0.30-3.00 |

Page 5 of 11
L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

Note
1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum
between 6-10 pm . The variation is of the order of 50%, hence time of the day has influence on the
measured serum TSH concentrations.
2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
3. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.
Clinical Use
 Primary Hypothyroidism
 Hyperthyroidism
 Hypothalamic - Pituitary hypothyroidism
 Inappropriate TSH secretion
 Nonthyroidal illness
 Autoimmune thyroid disease
 Pregnancy associated thyroid disorders
 Thyroid dysfunction in infancy and early childhood

Page 6 of 11
L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P
Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

URINE EXAMINATION, ROUTINE; URINE, R/E
(Automated Strip Test, Microscopy)

Physical

Colour Pale Yellow Pale yellow

Specific Gravity 1.010 1.001 - 1.030

pH 6.5 5.0 - 8.0

Chemical

Proteins Nil Nil

Glucose Nil Nil

Ketones Nil Nil

Bilirubin Nil Nil

Urobilinogen Normal Normal

Leucocyte Esterase Positive Negative

Nitrite Positive Negative

Microscopy

R.B.C. 2-3 RBC/HPF Negative

Pus Cells 18-20 WBC/HPF 0-5 WBC / hpf

Epithelial Cells Few Few

Casts Nil Nil /lpf

Crystals Nil Nil

Others Nil -

Bacteria present,results to be correlated clinically.

Page 7 of 11
L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD
(HPLC)

HbA1c 6.5 %

Estimated average glucose (eAG) 140 mg/dL

Interpretation
| As per American Diabetes Association (ADA) |
|-------------------------------------------------------------------------------|
| Reference Group | HbA1c in % |
|-------------------------------|-----------------------------------------------|
| Non diabetic adults >=18 years| 4.0 - 5.6 |
|-------------------------------|-----------------------------------------------|
| At risk (Prediabetes) | 5.7 - 6.4 |
|-------------------------------|-----------------------------------------------|
| Diagnosing Diabetes | >= 6.5 |
|-------------------------------|-----------------------------------------------|
| Therapeutic goals for glycemic| . Goal of therapy: < 7.0 |
| control | . Action suggested: > 8.0 |

Note
1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is
recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic
previously under good control but now poorly controlled
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no
significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or
extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate
3. Any condition that shortens erythrocyte survival such as sickle cell disease, pregnancy (second and third
trimesters), hemodialysis, recent blood loss or transfusion, or erythropoietin will falsely lower HbA1c results
regardless of the assay method
4. In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydroglucitol) test may be done to identify
those with more frequent and extreme hyperglycemic excursions

Comments
HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of
long term glycemic control as compared to blood and urinary glucose determinations. This single test can be used
both for diagnosing & monitoring diabetes. ADA recommends measurement of HbA1c 3-4 times per year in Type 1
diabetes and poorly controlled Type 2 diabetes patients. In well controlled Type 2 diabetes patients, the test can be
performed twice a year.

Page 8 of 11
L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

Page 9 of 11
L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

HEMOGRAM
(Flow Cytometery, SLS,Capillary Photometry )

Hemoglobin 11.00 g/dL 11.50 - 15.00

Packed Cell Volume (PCV) 40.00 % 36.00 - 46.00
RBC Count 3.90 mill/mm3 3.80 - 4.80
MCV 80.00 fL 80.00 - 100.00
MCH 30.00 pg 27.00 - 32.00
MCHC 33.00 g/dL 32.00 - 35.00
Red Cell Distribution Width (RDW) 11.00 % 11.50 - 14.50
Total Leukocyte Count (TLC) 8.90 thou/mm3 4.00 - 10.00
Differential Leucocyte Count (DLC)

Segmented Neutrophils 69.50 % 40.00 - 80.00

Lymphocytes 20.50 % 20.00 - 40.00

Monocytes 8.10 % 2.00 - 10.00

Eosinophils 1.80 % 1.00 - 6.00

Basophils 0.10 % <2.00

Absolute Leucocyte Count

Neutrophils 6.19 thou/mm3 2.00 - 7.00

Lymphocytes 1.82 thou/mm3 1.00 - 3.00

Monocytes 0.72 thou/mm3 0.20 - 1.00

Eosinophils 0.16 thou/mm3 0.02 - 0.50

Basophils 0.01 thou/mm3 0.01 - 0.10

Platelet Count 190.0 thou/mm3 150.00 - 450.00
ESR 10 mm/hr 0 - 20
Note
1. As per the recommendation of International council for Standardization in Hematology, the differential leucocyte
counts are additionally being reported as absolute numbers of each cell in per unit volume of blood

2. Test conducted on EDTA whole blood

Note
1. As per the recommendation of International council for Standardization in Hematology, the differential

Page 10 of 11
L55 - LPL Bengaluru Reference Lab
#17/1, "The Address" Opp Cessna Business
Park,Kadubeesanahalli,Bengaluru - 560103

Name : Mrs. DUMMY 2 Collected : 24/1/2019 11:20:00AM

Received : 24/1/2019 11:25:15AM
Lab No. : 262203463 Age: 30 Years Gender: Female Reported : 28/1/2019 1:09:13PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood

2. Test conducted on EDTA whole blood

Note
1. As per the recommendation of International council for Standardization in Hematology, the differential leucocyte
counts are additionally being reported as absolute numbers of each cell in per unit volume of blood

2. Test conducted on EDTA whole blood

Dr. Adithya S
MD(PATH)
Chief of Lab

-------------------------------End of report --------------------------------

IMPORTANT
INSTRUCTIONS

*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample repeats are
accepted on request of Referring Physician within 7 days post reporting. *Report delivery may be delayed due to unforeseen circumstances. Inconvenience is
regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.*Test
results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or
results of test(s).*Test results are not valid for medico legal purposes. * Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

Page 11 of 11